The MF market is advancing through diagnostic improvements and novel targeted therapies. Key players like Incyte, Sierra Oncology, and CTI BioPharma are developing next-generation JAK inhibitors and combination treatments that address symptom burden and disease progression. Enhanced treatment guidelines and prognostic tools are optimizing clinical management for this progressive myeloproliferative neoplasm.
View Market Insights:
https://shorturl.at/GFWha
Comment
Share
